Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million
Cambridge, MA, Jun 16— Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the close of its Series E financing round at a total of around $123 million, surpassing its initial target amid strong investor interest. The oversubscribed series E round further recognizes Insilico’s unique dual-engine business model, which combines a generative AI platform with deep in-house drug discovery capabilities to continuously enhance reinforcement learning, strengthen Pharma.AI, and drive scientific innovation.
The Series E financing was led by a private equity fund of Value Partners Group (HKG:0806), one of Asia’s largest independent asset management firms, with participation from a diverse group of new industry- and technology-focused investors, alongside continued support from Insilico’s existing global backers. Additional funding beyond the last announcement came from new investors including Grand Leader, as well as from Insilico’s existing investors, Prosperity7 Ventures.
The Series E funding will be allocated to advance Insilico’s innovative drug pipeline and further develop its AI platform to drive innovation in the pharmaceutical industry. A portion of the resources will be dedicated to refining AI models and algorithms, as well as updating and expanding Insilico’s state-of-the-art automated laboratory to further streamline R&D processes. Simultaneously, Insilico will prioritize the clinical validation of its AI-driven proprietary and partnered drug programs, thereby driving impactful innovations in healthcare.
“We are extremely grateful for the continued support from our investors, both new and existing, who share our vision for the future of AI-driven drug discovery and healthcare,” said Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine. “The oversubscribed completion of the Series E round is a milestone that not only accelerates the growth of our innovative pipeline and AI technologies but also underscores the industry’s recognition of our capabilities. We are committed to advancing transformative therapies and driving meaningful impact across the pharmaceutical landscape.”
“Positive feedback from investors has further reinforced our confidence.” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. “With multiple AI-driven R&D programs advancing in parallel, we are on track to become one of the first companies to successfully advance an AI-based drug candidate through clinical validation.”
Previously, Insilico announcedkey benchmarks demonstrating the ability of its proprietary AI platform to significantly reduce costs and improve efficiency in early drug discovery and development. By integrating AI and automation technologies, the company has built a wholly owned pipeline of over 30 assets, 10 of which have received IND clearance. This includes one asset that has completed a Phase IIa trial for idiopathic pulmonary fibrosis (IPF), another that has completed a multi-center Phase I trial for inflammatory bowel disease (IBD), and several additional oncology programs progressing into clinical trials.
Insilico has built sustainable revenue streams through a diversified business model centered on out-licensing deals for certain programs, taking into account drug discovery and pipeline development, software solutions, and other discovery related programs for non-pharma sectors. Since its inception in 2014, Insilico has published over 200 peer-reviewed papers and has held more than 640 patents and patent applications.
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico is extending the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.